STTK Stock Analysis: Shattuck Labs | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 673m USD | 12M Return: 840.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.44M
Qual. Beats: 0
Rev. Trend: 54.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Shattuck Labs is a clinical-stage biotechnology company based in Austin, Texas, founded in 2016. The company focuses on developing antibody-based therapeutics for inflammatory and immune-mediated diseases, relying on capital markets and potential partnerships rather than product revenue, which is typical of pre-commercial biotech firms.
Its lead program, SL-325, is a DR3-blocking monoclonal antibody currently in Phase I clinical trials. Shattuck is also advancing SL-425, a half-life extended version of SL-325, alongside preclinical DR3-based bispecific antibodies targeting inflammatory bowel disease and other immune indications, as well as an oncology-focused program called TRIM7.
- SL-325 Phase I trial progresses in DR3 antibody development
- Cash runway extension remains critical amid pipeline spending
- DR3 blockade faces competition from established immunology drug developers
| Net Income: -49.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA 32.72 > 1.0 |
| NWC/Revenue: 8.95k% < 20% (prev 109.8%; Δ 8.84k% < -1%) |
| CFO/TA -0.40 > 3% & CFO -41.3m > Net Income -49.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.2m) vs 12m ago 120.2% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.12% > 50% (prev 69.72%; Δ -68.61% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.88 (Total Current Assets 93.8m - Total Current Liabilities 4.25m) / Total Assets 102.1m |
| B: -4.36 (Retained Earnings -445.3m / Total Assets 102.1m) |
| C: -0.56 (EBIT TTM -49.9m / Avg Total Assets 89.6m) |
| D: 15.25 (Book Value of Equity 95.8m / Total Liabilities 6.29m) |
| Altman-Z'' = 3.80 = AA |
As of July 08, 2026, the stock is trading at USD 7.26 with a total of 1,427,433 shares traded. Over the past week, the price has changed by +5.99%, over one month by +86.15%, over three months by +7.08% and over the past year by +840.41%.
Current recommended Stop Loss: 5.60 (which is 22.9% or 2.7 ATR below the current price).
Shattuck Labs has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold STTK.
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.8 | 104.3% |
P/S = 673.3326
P/B = 6.4878
Revenue TTM = 1.00m USD
EBIT TTM = -49.9m USD
EBITDA TTM = -46.2m USD
Long Term Debt = 2.04m USD (estimated: total debt 2.89m - short term 852k)
Short Term Debt = 852k USD (from shortTermDebt, last quarter)
Debt = 2.89m USD (from shortLongTermDebtTotal, last quarter) (leases 2.89m already included)
Net Debt = -87.5m USD (calculated: Debt 2.89m - CCE 90.4m)
Enterprise Value = 585.8m USD (673.3m + Debt 2.89m - CCE 90.4m)
Interest Coverage Ratio = unknown (Ebit TTM -49.9m / Interest Expense TTM 0.0)
EV/FCF = -14.19x (Enterprise Value 585.8m / FCF TTM -41.3m)
FCF Yield = -7.05% (FCF TTM -41.3m / Enterprise Value 585.8m)
FCF Margin = -4.13k% (FCF TTM -41.3m / Revenue TTM 1.00m)
Net Margin = -4.99k% (Net Income TTM -49.9m / Revenue TTM 1.00m)
Gross Margin = unknown ((Revenue TTM 1.00m - Cost of Revenue TTM 3.69m) / Revenue TTM)
Tobins Q-Ratio = 5.74 (Enterprise Value 585.8m / Total Assets 102.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.89m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -39.4m (EBIT -49.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.06 (Total Current Assets 93.8m / Total Current Liabilities 4.25m)
Debt / Equity = 0.03 (Debt 2.89m / totalStockholderEquity, last quarter 95.8m)
Debt / EBITDA = 1.89 (negative EBITDA) (Net Debt -87.5m / EBITDA -46.2m)
Debt / FCF = 2.12 (negative FCF - burning cash) (Net Debt -87.5m / FCF TTM -41.3m)
Total Stockholder Equity = 82.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.64% (Net Income -49.9m / Total Assets 102.1m)
RoE = -60.73% (Net Income TTM -49.9m / Total Stockholder Equity 82.1m)
RoCE = -59.26% (EBIT -49.9m / Capital Employed (Equity 82.1m + L.T.Debt 2.04m))
RoIC = -39.93% (negative operating profit) (NOPAT -39.4m / Invested Capital 98.7m)
WACC = 11.76% (E(673.3m)/V(676.2m) * Re(11.81%) + D(2.89m)/V(676.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.21 | Cagr: 53.03%
[DCF] Fair Price = unknown (Cash Flow -41.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 54.94 | Revenue CAGR: 173.5% | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.13 | Chg30d=+3.87% | Revisions=+0% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+4.33% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-0.50 | Chg30d=-8.17% | Revisions=-50% | GrowthEPS=+28.5% | GrowthRev=-100.0%
EPS next Year (2027-12-31): EPS=-0.52 | Chg30d=-0.80% | Revisions=-25% | GrowthEPS=-3.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -36% (up=2, down=6)